Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists?

Abstract

Data on the treatment of sarcoidosis-associated pulmonary hypertension are scarce, while the variety of underlying pathophysiologic mechanisms are a major limitation in the implementation of a universal therapy. We report a 47-year-old male patient who presented with stage II sarcoidosis and associated severe pulmonary hypertension. Corticosteroid treatment resolved parenchymal lesions of the lung while vascular involvement did not respond, with the patient remaining in poor functional status. Addition of bosentan, a dual endothelin receptor antagonist, resulted in marked improvement in functional class and exercise capacity of the patient, allowing gradual tapering of steroids.

Keywords

bosentan pulmonary hypertension sarcoidosis

References

Barnett, C.F. , Bonura, E.J. , Nathan, S.D. , Ahmad, S. , Shlobin, O.A. , Osei, K. et al. (2009) Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 135: 1455-1461.

Baughman, R.P. ( 2007) Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 9(Suppl. 2): S8.

Fisher, K.A., Serlin, D.M., Wilson, K.C., Walter, R.E., Berman, J.S. and Farber, H.W. (2006)

Sarcoidosis-associated pulmonary hypertension. Outcome with long-term epoprostenol treatment. Chest 130: 1481-1488.

Kalra, P.R. , Moon, J.C. and Coats, A.J. ( 2002) Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195-197.

Letizia, C. , Danese, A. , Reale, M.G. , Caliumi, C. , Delfini, E. , Subioli, S. et al. (2001) Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 43: 257-261.

Milman, N. , Burton, C.M. , Iversen, M. , Videbaek, R. , Jensen, C.V. and Carlsen, J. ( 2008) Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 27: 329-334.

Nunes, H. , Humbert, M. , Capron, F. , Brauner, M. , Sitbon, O. , Battesti, J.P. et al. (2006) Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61: 68-74.

Preston, I.R. , Klinger, J.R. , Landzberg, M.J. , Houtchens, J. , Nelson, D. and Hill, N.S. ( 2001) Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120: 866-872.

10.

Reichenberger, F. , Schauer, J. , Kellner, K. , Sack, U. , Stiehl, P. and Winkler, J. ( 2001) Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 179: 163-174.

11.

Shigemitsu, H. , Nagai, S. and Sharma, O.P. ( 2007) Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 13: 434-438.

12.

Shorr, A.F. , Davies, D.B. and Nathan, S.D. ( 2003) Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124: 922-928.

13.

Simonneau, G. , Galiè, N. , Rubin, L.J. , Langleben, D. , Seeger, W. , Domenighetti, G. et al. (2004) Clinical classification of pulmonary hypertension . J Am Coll Cardiol 43(12 Suppl S): 5S-12S.

14.

Sofia, M. , Mormile, M. , Faraone, S. , Alifano, M. , Carratù, P. and Carratù, L. ( 1995) Endothelin excretion in urine in active pulmonary sarcoidosis and other interstitial lung disease. Sarcoidosis 12: 118-123.

15.

Terashita, K. , Kato, S. , Sata, M. , Inoue, S. , Nakamura, H. and Tomoike, H. ( 2006) Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 11: 145-151.